Barinthus Biotherapeutics (BRNS) Earnings Analysis

Barinthus Biotherapeutics (BRNS) has no confirmed upcoming earnings date. Last quarter (2026-04-30) it beat with EPS -0.14 USD vs -0.36 USD est (+61.1%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -0.47.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BRNS next report earnings?

No confirmed upcoming earnings date is currently scheduled for BRNS. This page updates as the calendar is published.

BRNS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-30-0.14 USD-0.36 USD+61.1%Beat
2026-03-13-0.27 USD-0.4 USD+32.5%Beat
2025-11-07-0.36 USD-0.45 USD+20%Beat
2025-08-07-0.52 USD-0.29 USD-79.3%Miss
2025-03-20-0.51 USD-0.5 USD-2%Miss
2024-08-08-0.43 USD-0.42 USD-2.4%Miss

Beat rate: 3/6 (50%) over reported quarters with consensus data.

BRNS valuation and analyst view

Trailing P/E-0.47
Trailing EPS-1.27998 USD
Price / book0.37
Dividend yield0.00%
Market cap0.03B
Analyst consensusBuy (3 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is Barinthus Biotherapeutics (BRNS)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for BRNS. This page updates as the calendar is published.

Did BRNS beat earnings last quarter?

In its 2026-04-30 report, BRNS posted EPS of -0.14 USD versus a -0.36 USD estimate — a beat of 61.1%.

What is BRNS's earnings track record?

Over the last 6 reported quarters with consensus data, BRNS beat estimates 3 times (50%).

What is BRNS's current P/E ratio and EPS?

BRNS trades at a trailing P/E of -0.47 on trailing EPS of -1.27997852965073 USD.

What do analysts rate BRNS?

Analyst consensus is "Buy" across 4 ratings (0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell).